Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Glucagon Aug 18 | 2020AZ to Withdraw Qtrilmet Marketing Authorization; CHMP Agenda August 17-20Purchase Blast
$599
Posted in: Dual/triple agonist Aug 18 | 2020Lilly's Next-gen Tirzepatide for Oral Delivery? New Lilly GIP/GLP Dual Agonist Ph1 StudiesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Aug 14 | 2020Novo Invests in Upgrading Kalundborg Manufacturing FacilityPurchase Blast
$599
Posted in: Glucagon Aug 13 | 2020Glucagon: Dasiglucagon Bi-hormonal Closed-Loop Pivotal Trial Delayed; Zealand Q2 '20 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other Aug 12 | 2020DarioHealth Q2 '20 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery Aug 11 | 2020Medtronic to Acquire Companion Medical; Thoughts on What It Could Mean for Insulin DeliveryPurchase Blast
$599
Posted in: Glucagon, Insulin Delivery, Other Aug 10 | 2020Ascensia Takes Over WW Eversense CGM Distribution; Xeris and Senseonics Q2 '20 Earnings Update; Precigen ActoBio Announces Positive Topline Results for T1DM ModulatorPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Aug 07 | 2020Novo Q2 '20 Roadshow; Provention Bio Q2 '20 Earnings Update; Senseonics Eversense Covered by HighmarkPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Aug 06 | 2020Mylan Filed for Glargine Interchangeability; Insulet, Mylan, and BD Q2 '20 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Aug 06 | 2020Novo Discontinues its Dual/Triple Agonists for Obesity; Novo Q2 '20 Earnings UpdatePurchase Blast
$599
Posted in: Bolus Insulin Aug 05 | 2020David Kendall to Leave MannKind; MannKind Q2 '20 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other, SGLT2i Aug 05 | 2020Livongo to Merge with Teladoc; AZ Partners for HF Diagnostic; ViaCyte Partners with Gore for Novel Membrane Development; Teva Q2 '20 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, Other, SGLT2i Aug 04 | 2020Merck In-licenses Hanmi's Dual Agonist for NASH; Generic Empagliflozin Tentative ApprovalPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Aug 03 | 2020Lilly Initiates New Connected Pen TrialPurchase Blast
$599
Posted in: Autologous, BCMA, CAR-T Jul 30 | 2020BMS and bluebird bio Resubmit Ide-cel to FDA; Dynamic H1 2021 BCMA Launch Environment Expected with JanssenPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Glucagon, Insulin Delivery, SGLT2i Jul 30 | 2020EMPEROR-Reduced Positive Topline Results; AZ Discontinues its GLP-1RA Small Molecule; Lexicon to Reorganize; Lilly, AZ, and Lexicon Q2 '20 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
